In a report published in Business Standard, cannabidiol (CBD), a non-psychotropic chemical compound found in marijuana may start appearing in medicines that fight osteoporosis and other bone-related diseases.
The findings are contained in the Journal of Bone and Mineral Research which cites that CBD, the principal agent in the study, is primarily anti-inflammatory and has no psychoactivity. On animal tests, researchers at Tel Aviv University and Hebrew University derived these findings who tested CBD on rats with cracks in their femurs.
The research and laboratory studies conclude that CBD leads to improvement in the healing of fractures and reveals the critical mechanical role of collagen cross-linking enzymes. Findings also show that CBD alone makes bones stronger during healing, improving the maturation of the collagenous matrix that provides the basis for new mineralization of bone tissue.
The research further cited that the endocannabinoid system in humans happens naturally and that the human body and brain are disposed to respond to cannabinoids.